Sunday, June 28, 2020 2:38:50 PM
https://www.scripps.edu/news-and-events/press-room/2020/20200612-choe-farzan-coronavirus-spike-mutation.html
The Galidesivir alternatives are failing. Hydroxychloroquine lost EAU, the Euro study of Actemra/Tocilizumab was ended early because it showed no benefit, Favipiravir causes birth defects, monoclonal antibodies & a COVID-19 vaccine are pipe dreams...
Remdesivir has EUA but the supply is nearly exhausted, it is toxic, expensive, marginally effective, the manufacturing is complex & it takes months to produce...
The exploding infection rates forced President Trump to have Dr Fauci & Dr Birx address the media this week after a prolonged absence. The COVID-19 infection rate is on the verge of spiraling out of control again in several states & cities, most notably Houston.
One third of tested Orlando airport workers were positive for COVID-19 last week. About 50,000 people pass thru there daily & travel all over the country...
Considering the above there is tremendous pressure on President Trump, Dr Fauci, NIH & NIAID to produce the next therapeutic...Galidesivir to the rescue...
Recall that Galidesivir falls under the FDA Animal Rule so there are two routes to Emergency Use Authorization, either thru human trials or animal trials. Gali already has animal trial successes verses Zika, Ebola, Yellow Fever & Marburg viruses. Also, CEO Stonehouse mentioned Gali COVID-19 animal studies in the 5/6/20 CC, perhaps they're completed???
The Galidesivir Brazilian clinical trial results are due "this summer", perhaps the data will be released this coming week???
So, there could be multiple factors involved but Galidesivir is my best bet for what caused the price/volume surge on Friday. I think Emergency Use Authorization for Gali will happen in July.
Recent BCRX News
- BioCryst to Report First Quarter 2024 Financial Results on May 6 • GlobeNewswire Inc. • 04/22/2024 11:00:50 AM
- BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency • GlobeNewswire Inc. • 04/17/2024 08:30:39 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2024 11:00:23 AM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/25/2024 08:01:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 03/05/2024 12:01:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:25:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 09:32:01 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 02/27/2024 10:05:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2024 12:05:56 PM
- BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones • GlobeNewswire Inc. • 02/26/2024 12:00:05 PM
- U.S. Index Futures Dip Amid Inflation Data Anticipation, Oil and Iron Ore Prices Retreat • IH Market News • 02/26/2024 10:57:28 AM
- BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment • GlobeNewswire Inc. • 02/23/2024 12:00:00 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 02/21/2024 09:01:58 PM
- BioCryst Launches ORLADEYO® (berotralstat) in Italy • GlobeNewswire Inc. • 02/19/2024 12:54:52 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:21:51 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 02:02:50 PM
- BioCryst to Report Fourth Quarter 2023 Financial Results on February 26 • GlobeNewswire Inc. • 02/12/2024 12:00:53 PM
- BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting • GlobeNewswire Inc. • 02/05/2024 12:00:00 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 02/02/2024 12:00:48 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/24/2024 10:23:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/18/2024 10:21:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:02:39 PM
- BioCryst Announces Preliminary Full Year 2023 ORLADEYO® (berotralstat) Net Revenue of $325 Million, Provides 2024 Guidance and Accelerated Path to Profitability • GlobeNewswire Inc. • 01/05/2024 09:01:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:31:49 PM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 01/03/2024 09:01:59 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM